4-imidazol-1-ylmethyl-pyrimidine derivatives
US6951864B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 6, 2003 |
| Grant date | Oct 4, 2005 |
| Priority date | — |
| Expiry date | May 27, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides 4-imidazol-1-ylmethyl pyrimidine of the formula that bind to GABAA receptors. In the above formula, R1, R2 R3, R4, R5, R6 and Ar are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.